Insuman Comb 25 (Insulin Human)

Insulin Human binds to insulin receptors on muscle, fat and liver cells, activating intracellular signaling pathways that promote glucose uptake, storage as glycogen, and inhibition of hepatic glucose production. This coordinated action reduces circulating glucose concentrations and supplies energy to cells.

The dose of Insuman Comb 25 is individualized. A qualified prescriber determines the amount, timing and frequency based on the patient’s age, weight, blood‑glucose targets, diet, activity level and response to therapy. Patients should follow the dosing instructions provided by their healthcare professional.

Insulin is generally considered the treatment of choice for diabetes in pregnancy because it does not cross the placenta in harmful amounts. However, the specific safety profile of Insuman Comb 25 in pregnancy or lactation should be evaluated by the prescribing clinician, who will weigh potential benefits against any risks.

To order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India supplies hospitals, pharmacies and procurement teams worldwide, then confirms pricing, availability, cold‑chain shipping details and necessary import documentation.

Insuman Comb 25 contains human insulin, whereas many newer analogues are modified to alter onset or duration. Human insulin provides a rapid‑acting profile similar to other short‑acting insulins but may differ in pharmacokinetics, dosing flexibility and cost. Clinicians choose based on patient needs, response, and formulary considerations.

Insuman Comb 25 should be stored in a refrigerator at 2‑8 °C, protected from light. Do not freeze or shake the vial. Once in use, it may be kept at controlled room temperature (up to 30 °C) for a limited period, typically 28 days, as indicated on the label.

Insuman Comb 25 is given by subcutaneous injection into the abdomen, thigh, or upper arm. The injection site should be rotated to reduce lipodystrophy. Patients should be trained by a healthcare professional on proper technique, needle length, and disposal of sharps.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from local rash to anaphylaxis. Rarely, patients may develop insulin antibodies that alter drug effectiveness. Prompt medical attention is required if any of these events occur.

Insuman Comb 25 is contraindicated in individuals with a known hypersensitivity to human insulin or any excipients in the formulation. It should also be avoided in patients experiencing hypoglycemia until glucose levels are corrected. Clinicians must assess each patient’s medical history before prescribing.